Gyre Therapeutics (GYRE) Equity Ratio (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Equity Ratio data on file, last reported at 0.85 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.85, up 5.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.85 (up 5.21% YoY), and the FY2025 annual result was 0.64, down 18.66% from the prior year.
• Equity Ratio climbed to 0.85 in Q1 2026 per GYRE's latest filing, from 0.64 in the prior quarter.
• Over five years, Equity Ratio peaked at 8.56 in Q3 2023 and troughed at 0.12 in Q4 2023.
• A 5-year average of 1.72 and a median of 0.8 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio soared 804.18% in 2023, then sank 90.82% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.85 in 2022, then slumped by 85.95% to 0.12 in 2023, then jumped by 555.56% to 0.78 in 2024, then dropped by 18.66% to 0.64 in 2025, then jumped by 32.48% to 0.85 in 2026.
• Business Quant data shows GYRE's Equity Ratio at 0.85 in Q1 2026, 0.64 in Q4 2025, and 0.64 in Q3 2025.